Upadacitinib, a reversible janus kinase (JAK) inhibitor targeting the JAK1 enzyme, is FDA-approved for use in individuals over 12 years old for many immunologic diseases, including moderate-to-severe atopic dermatitis. The gene discussed is JAK1; the disease is atopic eczema.